| VERASTEM INC. NEW |
| USA |
| Gesundheit |
| US92337C2035 / A3EHM3 |
| 2VSA (Frankfurt) / VSTM (NASDAQ) |
| FRA:2VSA, ETR:2VSA, 2VSA:GR, NASDAQ:VSTM |
| - |
| https://www.verastem.com/ |
|
Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway. Verastem Oncology’s current portfolio includes marketed and investigat..
>Volltext.. |
| 677.55 Mio. EUR |
| 631.95 Mio. EUR |
| 78.14 Mio. EUR |
| -141.64 Mio. EUR |
| -180.96 Mio. EUR |
| -2.2 EUR |
| 75.29 Mio. EUR |
| 121.73 Mio. EUR |
| -144.8 Mio. EUR |
| 1.75 |
| 4124.6% |
| -25.53% |
| - |
| - |
| - |
| VERASTEM |
| 14.10.26 |